|
Market Closed -
Nasdaq
04:00:00 2026-11-18 pm EST
|
5-day change | 1st Jan Change | ||
| 11.25 USD | -0.71% |
|
+10.40% | +82.93% |
| Nov. 13 | ImmuCell Corporation, Q3 2026 Earnings Call, Nov 13, 2026 | |
| Nov. 12 | ImmuCell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
Business description: ImmuCell Corporation

Number of employees: 73
Sales by Activity: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Scours | - | 18.41M | 17.29M | 26.31M | 27.45M |
Mastitis | - | 155K | 178K | 179K | 196K |
Biotechnology | 19.24M | - | - | - | - |
Other | - | 1.46K | - | - | - |
Geographical breakdown of sales: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 16.62M | 17.02M | 15.95M | 22.89M | 24.39M |
Other | 2.62M | 1.55M | 1.52M | 3.6M | 3.25M |
Executive Committee: ImmuCell Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 2025-10-31 | |
Timothy Fiori
DFI | Director of Finance/CFO | 47 | 2025-04-06 |
| Comptroller/Controller/Auditor | - | - |
Composition of the Board of Directors: ImmuCell Corporation
| Director | Title | Age | Since |
|---|---|---|---|
David Tomsche
CHM | Chairman | 69 | 2013-11-30 |
Paul Wainman
BRD | Director/Board Member | 61 | 2014-03-30 |
Gloria Basse
BRD | Director/Board Member | 66 | 2020-06-09 |
| Director/Board Member | 54 | 2025-10-31 | |
Kathy Turner
BRD | Director/Board Member | 62 | 2026-03-31 |
| Director/Board Member | 64 | 2026-04-14 | |
Anthony DiMarco
BRD | Director/Board Member | 63 | 2026-04-14 |
Company details: ImmuCell Corporation

Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.71% | +10.40% | +146.71% | +136.28% | 103M | ||
| -2.32% | -3.79% | +34.24% | +133.69% | 1,261B | ||
| -2.15% | -2.75% | +36.35% | +82.05% | 671B | ||
| -2.33% | -3.04% | +22.29% | +106.80% | 518B | ||
| -0.69% | +0.37% | +31.53% | +69.78% | 387B | ||
| -3.90% | -6.39% | +42.88% | +35.41% | 353B | ||
| -1.35% | -0.95% | +28.90% | +56.34% | 300B | ||
| -1.13% | -1.80% | +0.59% | +33.00% | 283B | ||
| -3.07% | -5.17% | +29.04% | +67.26% | 248B | ||
| -0.75% | -0.44% | +32.87% | +123.96% | 211B | ||
| Average | -1.84% | -0.60% | +40.54% | +84.46% | 423B | |
| Weighted average by Cap. | -2.09% | -2.34% | +30.59% | +91.57% |
- Stock Market
- Stocks
- ICCC Stock
- Company ImmuCell Corporation
Select your edition
All financial news and data tailored to specific country editions
















